Show simple item record

dc.contributor.authorDuffy, Michael J
dc.contributor.authorMullooly, Maeve
dc.contributor.authorO'Donovan, Norma
dc.contributor.authorSukor, Sumainizah
dc.contributor.authorCrown, John
dc.contributor.authorPierce, Aisling
dc.contributor.authorMcGowan, Patricia M
dc.date.accessioned2011-07-06T09:25:52Z
dc.date.available2011-07-06T09:25:52Z
dc.date.issued2011-06-09
dc.identifierhttp://dx.doi.org/10.1186/1559-0275-8-9
dc.identifier.citationClinical Proteomics. 2011 Jun 09;8(1):9
dc.identifier.urihttp://hdl.handle.net/10147/135433
dc.description.abstractAbstract The ADAMs are transmembrane proteins implicated in proteolysis and cell adhesion. Forty gene members of the family have been identified, of which 21 are believed to be functional in humans. As proteases, their main substrates are the ectodomains of other transmembrane proteins. These substrates include precursor forms of growth factors, cytokines, growth factor receptors, cytokine receptors and several different types of adhesion molecules. Although altered expression of specific ADAMs has been implicated in different diseases, their best-documented role is in cancer formation and progression. ADAMs shown to play a role in cancer include ADAM9, ADAM10, ADAM12, ADAM15 and ADAM17. Two of the ADAMs, i.e., ADAM10 and 17 appear to promote cancer progression by releasing HER/EGFR ligands. The released ligands activate HER/EGFR signalling that culminates in increased cell proliferation, migration and survival. Consistent with a causative role in cancer, several ADAMs are emerging as potential cancer biomarkers for aiding cancer diagnosis and predicting patient outcome. Furthermore, a number of selective ADAM inhibitors, especially against ADAM10 and ADAM17, have been shown to have anti-cancer effects. At least one of these inhibitors is now undergoing clinical trials in patients with breast cancer.
dc.titleThe ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
dc.typeJournal Article
dc.language.rfc3066en
dc.rights.holderDuffy et al.; licensee BioMed Central Ltd.
dc.description.statusPeer Reviewed
dc.date.updated2011-06-30T12:04:34Z
refterms.dateFOA2018-08-22T12:55:06Z
html.description.abstractAbstract The ADAMs are transmembrane proteins implicated in proteolysis and cell adhesion. Forty gene members of the family have been identified, of which 21 are believed to be functional in humans. As proteases, their main substrates are the ectodomains of other transmembrane proteins. These substrates include precursor forms of growth factors, cytokines, growth factor receptors, cytokine receptors and several different types of adhesion molecules. Although altered expression of specific ADAMs has been implicated in different diseases, their best-documented role is in cancer formation and progression. ADAMs shown to play a role in cancer include ADAM9, ADAM10, ADAM12, ADAM15 and ADAM17. Two of the ADAMs, i.e., ADAM10 and 17 appear to promote cancer progression by releasing HER/EGFR ligands. The released ligands activate HER/EGFR signalling that culminates in increased cell proliferation, migration and survival. Consistent with a causative role in cancer, several ADAMs are emerging as potential cancer biomarkers for aiding cancer diagnosis and predicting patient outcome. Furthermore, a number of selective ADAM inhibitors, especially against ADAM10 and ADAM17, have been shown to have anti-cancer effects. At least one of these inhibitors is now undergoing clinical trials in patients with breast cancer.


Files in this item

Thumbnail
Name:
1559-0275-8-9.xml
Size:
90.25Kb
Format:
XML
Thumbnail
Name:
1559-0275-8-9.pdf
Size:
452.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record